Scribe Therapeutics upsized IPO closes

Scribe Therapeutics Inc., a clinical-stage biotechnology company developing in vivo CRISPR gene editing therapies, completed an upsized initial public offering on the Nasdaq Global Market under the ticker 'SCTX'. The company sold 9,867,000 shares at $15.00 per share, including full exercise of the underwriters' option, raising approximately $155.51 million in gross proceeds (including a concurrent private placement). The IPO was priced at the high end of the $13-$15 range and was oversubscribed, reflecting strong investor demand. Scribe plans to use the proceeds to fund clinical development of its lead candidate STX-1150, a PCSK9-targeting epigenetic therapy for cardiovascular disease, as well as other pipeline programs. The company also completed a concurrent private placement of 500,000 shares to Sanofi, which had previously partnered with Scribe in a $1.5 billion research collaboration. The IPO is notable as the first for a gene editing company since Metagenomi's offering in February 2024, and it highlights a broader resurgence in biotech IPOs, which have delivered a weighted average return of 55% in 2026, outperforming AI-related listings.